Eli Lilly has struck a deal worth up to $2.75 billion with Hong Kong-listed Insilico Medicine, handing the AI drug discovery company $115 million upfront in exchange for global commercialisation rights to a selection of its AI-developed drug candidates.
The agreement, first reported by the Financial Times, marks a significant bet by one of the world's most valuable pharmaceutical companies on AI-generated pipelines. The headline figure is weighted heavily toward milestone payments, a structure typical of biotech licensing, with the $115 million upfront representing the floor of Lilly's immediate financial commitment.
Insilico, which is listed in Hong Kong, uses generative AI and machine learning to identify novel drug targets and design molecules, a process the company argues can compress discovery timelines substantially compared with conventional methods. The deal gives Lilly global market access to drugs that Insilico's platforms have already advanced through early development.
For Lilly, the transaction continues an aggressive expansion of its pipeline beyond its blockbuster GLP-1 franchise. The Indianapolis-based group has a market capitalisation of roughly $700 billion and has been deploying capital across internal research and external partnerships as it seeks to sustain growth once its obesity and diabetes drugs face generic competition.
The deal also signals rising confidence among large pharmaceutical buyers that AI-native companies can deliver candidates worth licensing at scale, rather than merely accelerating internal research workflows.
